Skip to main content
Signal8
Launch Terminal

TELA Bio, Inc. (TELA)

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

TELA Bio, Inc. logo

TELA Bio, Inc.

NASDAQ:TELAHealthcare
-11.95%$0.8101
AH$0.8101+0.00%vs close
Mkt Cap$36.57M
Float36.89M
O/S45.14M
Vol
$ Vol
RVOL
Inst Own57.0%
SI1.7%
Earnings
Dilution
TELA Bio, Inc. logoNASDAQ:TELA$0.8101-11.95%
Phase Distribution
5 lead-sponsored trials·4 active·1 completed
Not applicable5
Status Overview
Recruiting3
Active, not recruiting1
Completed1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
  • Not applicable
    Completed

    Ventral Hernia Study Using OviTex Reinforced Bioscaffold

    OviTex 1S Permanent

    Hernia, Ventral

    Enrollment
    92
    Start
    Apr 2017
    Primary Completion
    Dec 2019
    Completion
    Aug 2021
    NCT03074474
  • Not applicable
    Recruiting

    Ventral or Inguinal Hernia, Robotically Repaired With OviTex Mesh

    OviTex Reinforced Tissue Matrix

    Hernia, Ventral, Hernia, Inguinal

    Enrollment
    160
    Start
    Apr 2021
    Primary Completion
    Mar 2027est.
    Completion
    Dec 2029est.
    NCT04779918
  • Observational
    Active, not recruiting

    A Retrospective Assessment of OviTex PRS (OviTex)

    OviTex® PRS

    Reconstructive Surgical Procedures

    Enrollment
    200
    Start
    Sep 2022
    Primary Completion
    Aug 2026est.
    Completion
    Dec 2026est.
    NCT05736848
  • Not applicable
    Recruiting

    Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®

    OviTex Reinforced Tissue Matrix

    Hiatal Hernia

    Enrollment
    173
    Start
    Jul 2025
    Primary Completion
    Dec 2031est.
    Completion
    Jul 2032est.
    NCT07070115
  • Not applicable
    Recruiting

    Effectiveness and Safety of OviTex® PRS in Breast Reconstruction

    OviTex PRS

    Breast Reconstruction

    Enrollment
    235
    Start
    Apr 2026
    Primary Completion
    Jun 2030est.
    Completion
    Jun 2034est.
    NCT07135596
Search ClinicalTrials.gov for “TELA Bio”